CD8A and neoplasm: These data collectively suggest that treatment with SAS or AS101 may decrease tumor volume in B16/F10 melanoma-bearing mice, at least in part, through their ability to decrease PD-L1 expression on tumor cells, enabling more CD8+ cells to infiltrate into the tumor and induce tumor cell death.